Corcept Therapeutics (CORT) Director G Leonard Baker, Jr. Sells 30,000 Shares of Stock

Corcept Therapeutics (NASDAQ:CORT) Director G Leonard Baker, Jr. sold 30,000 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $16.01, for a total transaction of $480,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Corcept Therapeutics opened at $17.61 on Wednesday, MarketBeat.com reports. Corcept Therapeutics has a 12 month low of $16.97 and a 12 month high of $17.90. The company has a market cap of $1.98 billion, a PE ratio of 33.00 and a beta of 1.92.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.01. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The business had revenue of $57.66 million during the quarter, compared to analysts’ expectations of $58.18 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The company’s quarterly revenue was up 108.9% compared to the same quarter last year. research analysts forecast that Corcept Therapeutics will post 0.73 EPS for the current fiscal year.

Several research firms have weighed in on CORT. ValuEngine raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Zacks Investment Research raised Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Friday, April 27th. Seaport Global Securities initiated coverage on Corcept Therapeutics in a research note on Friday, April 13th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, B. Riley initiated coverage on Corcept Therapeutics in a research note on Thursday, March 8th. They issued a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $25.17.

A number of large investors have recently added to or reduced their stakes in CORT. We Are One Seven LLC purchased a new position in Corcept Therapeutics in the fourth quarter worth $106,000. Tyers Asset Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $136,000. Asset Management One Co. Ltd. purchased a new position in Corcept Therapeutics in the first quarter worth $150,000. Riverhead Capital Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $155,000. Finally, Flinton Capital Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $173,000. Hedge funds and other institutional investors own 75.98% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit